Wound Closure

Plus Antibacterial Suture Portfolio

Take greater control of key risk factors related to Surgical Site Infections (SSIs)

The petri dish image is for illustrative purposes only, zone of inhibition testing results can vary.

The Who, and ACS & SIS suggests the use of triclosan-coated sutures. The WHO suggests use these types of sutures in their Global Guidelines for the Prevention of Surgical Site Infections, and the ACS and SIS recommend use in their updated Surgical Site Infection Guidelines. These updated guidelines support our decade-long commitment to helping surgeons and their institutions address the overwhelming burden of healthcare associated infections.

‡ The WHO, ACS & SIS Guidelines on reducing the risk of surgical site infections are general to triclosan-coated sutures and are not specific to any one brand.

WHO Recommendation

"The panel suggests the use of triclosan-coated sutures for the purpose of reducing the risk of SSI, independent of the type of surgery."– “Conditional” Recommendation with “Moderate” Quality of Evidence

ACS and SIS Recommendation

Ethicon has a portfolio offering of triclosan-coated sutures.

‡ The WHO, ACS & SIS Guidelines on reducing the risk of surgical site infections are general to triclosan-coated sutures and are not specific to any one brand.

Suture selection provides an important opportunity to address an associated risk factor for infection—bacterial colonization on the suture. Numerous studies have demonstrated that antibacterial sutures inhibit the growth of bacteria commonly associated with suture-related SSI, including137,138,146*:

  • Staphylococcus aureus
  • Staphylococcus epidermidis
  • Methicillin-resistant S. aureus (MRSA)
  • Methicillin-resistant S. epidermidis (MRSE)
  • Escherichia coli**
  • Klebsiella pneumonia**

The antibacterial component of all Plus Sutures -- IRGACARE® MP—represents the purest form of triclosan, shown to inhibit colonization on the device in vitro for seven days or more, while providing a favorable safety profile spanning over 40 years.137,138,146, 552 The use of antibacterial sutures is mentioned in infection prevention guidelines supported by the Association for Professionals in Infection Control and Epidemiology (APIC).556

For complete product details, see Instructions for Use.

The Plus Antibacterial Suture portfolio includes

  • MONOCRYL® Plus Antibacterial (poliglecaprone 25) Suture
  • Coated VICRYL® Plus Antibacterial (polyglactin 910) Suture
  • PDS® Plus Antibacterial (polydioxanone) Suture

The petri dish image is for illustrative purposes only, zone of inhibition testing results can vary.

The STRATAFIX™ Knotless Tissue Control Device portfolio now contains three devices with Plus Antibacterial Technology

  • STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device
  • STRATAFIX™ Spiral MONOCRYL™ Plus Knotless Tissue Control Device
  • STRATAFIX™ Spiral PDS™ Plus Knotless Tissue Control Device

Click either link below for more information

Descriptions & Specifications


Science & Technology

Site References

  • *Coated VICRYL® Plus Antibacterial (polyglactin 910) Suture, MONOCRYL® Plus Antibacterial (poliglecaprone 25) Suture, and PDS® Plus Antibacterial (polydioxanone) Suture are active in vitro against Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), Staphylococcus epidermis, and methicillin-resistant S. epidermis (MRSE).
  • †Trademark of BASF SE.
  • ** MONOCRYL Plus Suture and PDS Plus Suture have also demonstrated activity against Klebsiella pneumoniae and Escherichia coli in vitro.
X
Thanks for submitting the question. Thanks for submitting the question. Thanks for submitting the question. Thanks for submitting the question. on dev
X
Share with Friends

Interested in sharing this item?

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.
X
Device Code Translator
X
Device code translator results

Back to Search